These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
If fatigue persists beyond the first few weeks at a stable dose, mention this to your healthcare provider
Similar Products see all More from APLB see all Frequently Bought Together see all The information provided herein is accurate, updated and complete as per the best practices of the Company
This is a long-term medication, says Dr
Mochi offers FDA-approved brand-name GLP-1s, but compounded options are not FDA-approved, and labs are not required before starting